News

Video

ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL

Data show excellent refractive stability, strong visual acuity across all distances, and contrast sensitivity comparable to monofocal IOLs.

Steven J. Dell, MD, of Dell Laser Consultants, Austin, Texas, presented the 24-month refractive stability and visual acuity data for the OmniVu accommodating IOL (Atia Vision) at the 2025 American Society of Cataract and Refractive Surgery annual meeting, held April 25 to 28, in Los Angeles, California. Reporting on 19 patients (29 eyes), Dell noted, “It was frankly some of the best data that I've ever seen on refractive predictability for any IOL of any type.”

The lens demonstrated excellent refractive stability over 24 months, with strong alignment between early postoperative, 1-year, and 2-year data. Patients achieved excellent uncorrected distance, intermediate, and near vision. Critically, for binocular vision at intermediate distance through the distance correction, mean acuity was 20/20, and for near, 20/25. “Very, very good data and very functional vision throughout the visual spectrum,” Dell emphasized.

The lens' unique dual-optic design — with a fluid-filled posterior optic responsive to ciliary muscle contraction and a fixed anterior optic — aims to deliver stable, predictable refractive outcomes. Its bag-filling approach helps maintain capsular clarity and mimics the size of the natural crystalline lens. “The quality of vision with this design is comparable to any monofocal IOL,” Dell said, highlighting minimal dysphotopsia and a continuous range of clear vision, long sought after in accommodating lens technology.

He was also pleased to report that “contrast sensitivity data was really comparable to what we see with monofocal IOLs,” and that both astigmatism and spherical equivalent remained stable across the 24-month follow-up.

“There are a number of accommodating IOL designs out there,” Dell concluded, “but I think it's fair to say that the Atia Vision OmniVu lens is the one that is furthest into the process.”

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
(Image credit: Ophthalmology Times) NeuroOp Guru: Using OCT to forecast outcomes in ethambutol optic neuropathy
(Image credit: Ophthalmology Times) Inside NYEE’s new refractive solutions center with Kira Manusis, MD
(Image credit: Ophthalmology Times) Dilsher Dhoot, MD, on the evolution of geographic atrophy therapy: where are we now?
(Image credit: Ophthalmology Times Europe) Anat Loewenstein, MD, shares insights on the real-world results of remote retinal imaging
(Image credit: Ophthalmology Times) Two-wavelength autofluorescence for macular xanthophyll carotenoids with Christine Curcio, PhD
(Image credit: Ophthalmology Times) FLIO and the brain: Making the invisible visible with Robert Sergott, MD
(Image credit: Ophthalmology Times) Structure-function correlates using high-res OCT images with Karl Csaky, MD, PhD
(Image credit: Ophthalmology Times) SriniVas Sadda, MD, on high-res OCT of atrophic and precursor lesions in AMD
(Image credit: Ophthalmology Times) Christine Curcio, PhD, shares histology update supporting review software and revised nomenclature for <3 μm OCT
© 2025 MJH Life Sciences

All rights reserved.